Posted on 05/03/2010 in Pharmaceutical Company Product News Bristol-Myers Squibb has received backing from a new clinical study over the efficacy of its oral anticoagulant apixaban, which it developed with Pfizer.
Results from the phase III ADVANCE-2 study showed that patients undergoing elective total knee replacement surgery showed a reduced risk of suffering venous thromboembolism when using the treatment.
It compared favourably to the alternative 40 mg once daily enoxaparin treatment in terms of effectiveness, as well as resulting in lower rates of bleeding as a side effect.
Dr Michael Rud Lassen of the Hoersholm Hospital in Copenhagen, who was the lead investigator for the study, said this risk of bleeding is normally a "major concern" for orthopaedic surgeons.
He added: "We are encouraged by the ADVANCE-2 data, which demonstrated better antithrombotic effect and comparable bleeding rates for apixaban compared with enoxaparin."
Earlier this week, Bristol-Myers Squib agreed a new collaboration with Allergan on the development of a new treatment for neuropathic pain.Other news stories from 05/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
